Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8129888 | PMC |
| http://dx.doi.org/10.1016/j.eclinm.2021.100871 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Antitubercular potential and pH-driven mode of action of salicylic acid derivatives.
FEBS Open Bio
December 2024
CNRS, LISM, IMM FR3479, Aix Marseille Univ, France.
In the search for new antituberculosis drugs with novel mechanisms of action, we evaluated the antimycobacterial activity of a panel of eight phenolic acids against four pathogenic mycobacterial model species, including Mycobacterium tuberculosis. We demonstrated that salicylic acid (SA), as well as the iodinated derivatives 5-iodo-salicylic acid (5ISA) and 3,5-diiodo-salicylic acid (3,5diISA), displayed promising antitubercular activities. Remarkably, using a genetically encoded mycobacterial intrabacterial pH reporter, we describe for the first time that SA, 5ISA, 3,5diISA, and the anti-inflammatory drug aspirin (ASP) act by disrupting the intrabacterial pH homeostasis of M.
View Article and Find Full Text PDFGenetic insights into the connection between pulmonary TB and non-communicable diseases: An integrated analysis of shared genes and potential treatment targets.
PLoS One
October 2024
Institute of Information Technology, Jahangirnagar University, Dhaka, Bangladesh.
Article Synopsis
- Pulmonary Tuberculosis (PTB) is a major global health concern due to its prevalence and links to drug resistance, particularly impacting individuals with weakened immune systems, while also contributing to a rise in noncommunicable diseases (NCDs).
- This study investigates the genetic connections between PTB and seven specific NCDs, aiming to uncover drug components that can potentially regulate gene expression and facilitate targeted treatment strategies.
- Various analyses identified nine shared genes between PTB and NCDs, with five hub genes selected for their significance in understanding the relationship and improving therapeutic approaches.
Article Synopsis
- - Tuberculous meningitis (TBM) is a severe form of tuberculosis that can lead to significant health issues if not diagnosed and treated promptly, which is highlighted in a case involving a 9-month-old girl with neurological symptoms.
- - Initially misdiagnosed with an ischemic stroke and treated accordingly, her ongoing health problems prompted further testing that ultimately revealed TBM.
- - The case emphasizes the need to consider TBM in young patients presenting with neurological issues, especially during the COVID-19 pandemic when symptoms may overlap with those of other viral infections.
Pharmacokinetic and Bioequivalence Evaluation of Dihydroxyaluminum Aminoacetate, Heavy Magnesium Carbonate, and Aspirin Tablets in Healthy Chinese Subjects in the Fasting and Postprandial Conditions.
Clin Pharmacol Drug Dev
October 2024
Phase I Clinical Research Centre, Wuhan Pulmonary Hospital, Wuhan Tuberculosis Prevention and Control Institution, Wuhan, China.
Dihydroxyaluminum aminoacetate, heavy magnesium carbonate, and aspirin tablets is a new combined aspirin preparation, each containing aspirin (81 mg), dihydroxyaluminum aminoacetate (11 mg), and heavy magnesium carbonate (22 mg). This study was conducted to evaluate the pharmacokinetic (PK) and bioequivalence in healthy Chinese subjects. This randomized, open-label, single-dose, 2-sequence, and 2-period crossover study included 78 healthy volunteers (fasting, n = 36; postprandial, n = 42).
View Article and Find Full Text PDFDeveloping biomarker assays to accelerate tuberculosis drug development: defining target product profiles.
Lancet Microbe
September 2024
Division of Infectious Diseases and Tropical Medicine, University Hospital, Ludwig-Maximilians-Universität München (LMU), Munich, Germany; German Center for Infection Research (DZIF), Partner Site Munich, Munich, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology, Infection and Pandemic Research, Munich, Germany.
Drug development for tuberculosis is hindered by the methodological limitations in the definitions of patient outcomes, particularly the slow organism growth and difficulty in obtaining suitable and representative samples throughout the treatment. We developed target product profiles for biomarker assays suitable for early-phase and late-phase clinical drug trials by consulting subject-matter experts on the desirable performance and operational characteristics of such assays for monitoring of tuberculosis treatment in drug trials. Minimal and optimal criteria were defined for scope, intended use, pricing, performance, and operational characteristics of the biomarkers.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!